Ardelyx (ARDX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ARDX Stock Forecast


Ardelyx stock forecast is as follows: an average price target of $8.75 (represents a 64.78% upside from ARDX’s last price of $5.31) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

ARDX Price Target


The average price target for Ardelyx (ARDX) is $8.75 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $2.00. This represents a potential 64.78% upside from ARDX's last price of $5.31.

ARDX Analyst Ratings


Buy

According to 8 Wall Street analysts, Ardelyx's rating consensus is 'Buy'. The analyst rating breakdown for ARDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Ardelyx Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 05, 2024Ed ArceH.C. Wainwright--81.82%107.16%
Jul 05, 2024Ed ArceH.C. Wainwright--89.04%88.32%
May 24, 2024Christopher RaymondRaymond James--108.31%182.49%
Dec 18, 2023Ryan DeschnerRaymond James--90.33%125.99%
Dec 30, 2022Citigroup--145.61%31.83%
Dec 29, 2022Laura ChicoWedbush---14.35%-62.34%
Row per page
Go to

The latest Ardelyx stock forecast, released on Aug 05, 2024 by Ed Arce from H.C. Wainwright, set a price target of $11.00, which represents a 81.82% increase from the stock price at the time of the forecast ($6.05), and a 107.16% increase from ARDX last price ($5.31).

Ardelyx Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$12.00
Last Closing Price$5.31$5.31$5.31
Upside/Downside-100.00%-100.00%125.99%

In the current month, the average price target of Ardelyx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ardelyx's last price of $5.31. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 05, 2024H.C. WainwrightBuyBuyHold
Aug 02, 2024WedbushBuyBuyHold
Jul 05, 2024H.C. WainwrightBuyBuyHold
Jul 02, 2024Piper SandlerOverweightNeutralDowngrade
Jun 20, 2024WedbushBuyBuyHold
May 24, 2024Piper SandlerOverweightOverweightHold
May 24, 2024WedbushBuyBuyHold
May 03, 2024Cowen & Co.BuyBuyHold
May 03, 2024CitigroupBuyBuyHold
Apr 05, 2024WedbushBuyBuyHold
Row per page
Go to

Ardelyx's last stock rating was published by H.C. Wainwright on Aug 05, 2024. The company gave ARDX a "Buy" rating, the same as its previous rate.

Ardelyx Financial Forecast


Ardelyx Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$56.39M$22.33M$11.37M$44.18M$4.99M$2.53M$468.00K$1.03M$1.17M$1.31M$6.58M$1.81M$2.71M$1.84M$1.21M$2.25M$3.01M
Avg Forecast$181.50M$172.00M$164.50M$157.00M$110.73M$101.97M$93.02M$83.32M$108.56M$86.64M$55.03M$36.40M$34.06M$22.57M$15.28M$10.41M$23.18M$3.92M$2.22M$875.00K$875.50K$1.32M$940.00K$1.38M$1.66M$1.36M$1.81M$550.00K$975.00K$150.00K
High Forecast$233.86M$221.62M$211.96M$202.29M$142.68M$131.38M$119.86M$123.96M$125.56M$86.84M$55.03M$36.40M$37.65M$24.09M$19.69M$13.41M$29.86M$3.92M$2.22M$875.00K$875.50K$1.32M$940.00K$1.38M$1.66M$1.36M$1.81M$550.00K$975.00K$150.00K
Low Forecast$153.57M$145.53M$139.19M$132.84M$93.69M$86.28M$78.71M$65.50M$98.26M$86.44M$55.03M$36.40M$32.16M$20.81M$12.93M$8.80M$19.61M$3.92M$2.22M$875.00K$875.50K$1.32M$940.00K$1.38M$1.66M$1.36M$1.81M$550.00K$975.00K$150.00K
# Analysts3333444684445763222234566889127
Surprise %-------------2.50%1.46%1.09%1.91%1.27%1.14%0.53%1.18%0.89%1.40%4.79%1.09%2.00%1.01%2.21%2.31%20.09%

Ardelyx's average Quarter revenue forecast for Dec 23 based on 5 analysts is $34.06M, with a low forecast of $32.16M, and a high forecast of $37.65M. ARDX's average Quarter revenue forecast represents a -39.60% decrease compared to the company's last Quarter revenue of $56.39M (Sep 23).

Ardelyx EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3333444684445763222234566889127
EBITDA-------------$7.40M$-16.62M$-24.76M$12.52M$-20.55M$-25.97M$-27.09M$-35.06M$-41.91M$-43.62M$-31.63M$-27.14M$-16.47M$-23.26M$-20.52M$-17.88M$-21.16M
Avg Forecast$-161.35M$-152.90M$-146.23M$-139.57M$-98.43M$-90.64M$-82.69M$-74.07M$-96.51M$-77.02M$-48.92M$-45.32M$-30.28M$-20.06M$-13.58M$-35.83M$-37.28M$-3.49M$-1.97M$-28.32M$-778.28K$-1.17M$-835.62K$-30.67M$-1.48M$-1.21M$-1.61M$-20.52M$-866.73K$-133.34K
High Forecast$-136.52M$-129.37M$-123.73M$-118.09M$-83.29M$-76.70M$-69.97M$-58.23M$-87.35M$-76.84M$-48.92M$-36.26M$-28.59M$-18.50M$-11.49M$-28.66M$-29.82M$-3.49M$-1.97M$-22.66M$-778.28K$-1.17M$-835.62K$-24.54M$-1.48M$-1.21M$-1.61M$-16.42M$-866.73K$-133.34K
Low Forecast$-207.89M$-197.01M$-188.42M$-179.83M$-126.83M$-116.79M$-106.55M$-110.19M$-111.62M$-77.20M$-48.92M$-54.39M$-33.47M$-21.41M$-17.50M$-42.99M$-44.73M$-3.49M$-1.97M$-33.99M$-778.28K$-1.17M$-835.62K$-36.81M$-1.48M$-1.21M$-1.61M$-24.63M$-866.73K$-133.34K
Surprise %--------------0.37%1.22%0.69%-0.34%5.89%13.15%0.96%45.04%35.79%52.20%1.03%18.36%13.63%14.47%1.00%20.63%158.65%

5 analysts predict ARDX's average Quarter EBITDA for Dec 23 to be $-30.28M, with a high of $-28.59M and a low of $-33.47M. This is -509.27% lower than Ardelyx's previous annual EBITDA (Sep 23) of $7.40M.

Ardelyx Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3333444684445763222234566889127
Net Income-------------$6.63M$-17.12M$-26.77M$10.70M$-23.91M$-26.94M$-28.07M$-37.22M$-43.59M$-45.19M$-33.16M$-28.88M$-18.11M$-24.96M$-22.37M$-19.79M$-23.54M
Avg Forecast$49.54M$42.46M$37.75M$33.03M$4.13M$-2.77M$-9.19M$-18.83M$1.25M$-11.57M$-25.01M$-46.96M$-22.34M$-25.38M$-27.20M$-37.12M$-38.53M$-39.50M$-45.18M$-29.35M$-71.26M$-82.42M$-85.71M$-32.15M$-61.28M$-66.32M$-62.75M$-22.37M$-76.20M$-86.79M
High Forecast$68.12M$58.39M$51.90M$45.42M$5.67M$-2.22M$-7.35M$-9.16M$4.99M$-9.25M$-20.01M$-37.57M$-9.93M$-13.84M$-21.76M$-29.70M$-30.82M$-39.50M$-45.18M$-23.48M$-71.26M$-82.42M$-85.71M$-25.72M$-61.28M$-66.32M$-62.75M$-17.90M$-76.20M$-86.79M
Low Forecast$39.63M$33.97M$30.19M$26.42M$3.30M$-3.81M$-12.64M$-24.42M$-4.99M$-15.91M$-34.39M$-56.35M$-27.30M$-34.61M$-37.40M$-44.55M$-46.23M$-39.50M$-45.18M$-35.22M$-71.26M$-82.42M$-85.71M$-38.58M$-61.28M$-66.32M$-62.75M$-26.85M$-76.20M$-86.79M
Surprise %--------------0.26%0.63%0.72%-0.28%0.61%0.60%0.96%0.52%0.53%0.53%1.03%0.47%0.27%0.40%1.00%0.26%0.27%

Ardelyx's average Quarter net income forecast for Dec 23 is $-22.34M, with a range of $-27.30M to $-9.93M. ARDX's average Quarter net income forecast represents a -436.95% decrease compared to the company's last Quarter net income of $6.63M (Sep 23).

Ardelyx SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3333444684445763222234566889127
SG&A-------------$32.66M$27.19M$26.80M$19.73M$18.67M$18.86M$19.34M$15.33M$19.71M$20.12M$17.13M$11.34M$7.63M$7.04M$7.14M$6.86M$6.92M
Avg Forecast$678.21M$642.71M$614.69M$586.66M$413.76M$381.02M$347.59M$311.34M$405.66M$323.76M$205.63M$32.35M$127.27M$84.33M$57.10M$38.88M$16.31M$14.65M$8.30M$3.27M$3.27M$4.92M$3.51M$5.14M$6.21M$5.08M$6.76M$2.06M$3.64M$560.50K
High Forecast$873.87M$828.13M$792.02M$755.91M$533.13M$490.94M$447.88M$463.18M$469.18M$324.50M$205.63M$38.82M$140.70M$90.00M$73.58M$50.10M$19.57M$14.65M$8.30M$3.27M$3.27M$4.92M$3.51M$5.14M$6.21M$5.08M$6.76M$2.06M$3.64M$560.50K
Low Forecast$573.85M$543.81M$520.10M$496.39M$350.10M$322.39M$294.11M$244.75M$367.16M$323.01M$205.63M$25.88M$120.17M$77.78M$48.32M$32.90M$13.04M$14.65M$8.30M$3.27M$3.27M$4.92M$3.51M$5.14M$6.21M$5.08M$6.76M$2.06M$3.64M$560.50K
Surprise %-------------0.39%0.48%0.69%1.21%1.27%2.27%5.91%4.69%4.01%5.73%3.33%1.83%1.50%1.04%3.47%1.88%12.35%

Ardelyx's average Quarter SG&A projection for Dec 23 is $127.27M, based on 5 Wall Street analysts, with a range of $120.17M to $140.70M. The forecast indicates a 289.64% rise compared to ARDX last annual SG&A of $32.66M (Sep 23).

Ardelyx EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3333444684445763222234566889127
EPS-------------$0.03$-0.00$-0.13$0.06$-0.14$-0.19$-0.21$-0.32$-0.42$-0.45$-0.34$-0.32$-0.20$-0.28$-0.25$-0.27$-0.37
Avg Forecast$0.21$0.18$0.16$0.14$0.02$-0.01$-0.04$-0.08$0.01$-0.05$-0.11$-0.15$-0.09$-0.11$-0.12$-0.10-$-0.17$-0.19$-0.22$-0.30$-0.35$-0.37$-0.33$-0.26$-0.28$-0.27$-0.25$-0.32$-0.37
High Forecast$0.29$0.25$0.22$0.19$0.02$-0.01$-0.03$-0.04$0.02$-0.04$-0.08$-0.12$-0.04$-0.06$-0.09$-0.08-$-0.17$-0.19$-0.22$-0.30$-0.35$-0.37$-0.33$-0.26$-0.28$-0.27$-0.25$-0.32$-0.37
Low Forecast$0.17$0.14$0.13$0.11$0.01$-0.02$-0.05$-0.10$-0.02$-0.07$-0.15$-0.20$-0.12$-0.15$-0.16$-0.14-$-0.17$-0.19$-0.22$-0.30$-0.35$-0.37$-0.33$-0.26$-0.28$-0.27$-0.25$-0.32$-0.37
Surprise %--------------0.28%0.00%1.29%25.92%0.83%0.99%0.95%1.05%1.20%1.23%1.03%1.22%0.71%1.05%1.00%0.83%1.00%

According to 5 Wall Street analysts, Ardelyx's projected average Quarter EPS for Dec 23 is $-0.09, with a low estimate of $-0.12 and a high estimate of $-0.04. This represents a -415.60% decrease compared to ARDX previous annual EPS of $0.03 (Sep 23).

Ardelyx Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals--10506.06%Buy
LXRXLexicon Pharmaceuticals--597.67%Buy
INZYInozyme Pharma--422.06%Buy
PDSBPDS Bio--330.62%Buy
ZURAZura Bio--266.30%Buy
TERNTerns Pharmaceuticals--146.11%Buy
VSTMVerastem--108.25%Buy
MREOMereo BioPharma Group--81.45%Buy
ARDXArdelyx--64.78%Buy
MCRBSeres Therapeutics--62.34%Buy
IBRXImmunityBio--56.86%Buy
HOOKHOOKIPA Pharma--39.53%Buy

ARDX Forecast FAQ


Is Ardelyx a good buy?

Yes, according to 8 Wall Street analysts, Ardelyx (ARDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of ARDX's total ratings.

What is ARDX's price target?

Ardelyx (ARDX) average price target is $8.75 with a range of $2 to $15, implying a 64.78% from its last price of $5.31. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ardelyx stock go up soon?

According to Wall Street analysts' prediction for ARDX stock, the company can go up by 64.78% (from the last price of $5.31 to the average price target of $8.75), up by 182.49% based on the highest stock price target, and down by -62.34% based on the lowest stock price target.

Can Ardelyx stock reach $8?

ARDX's average twelve months analyst stock price target of $8.75 supports the claim that Ardelyx can reach $8 in the near future.

What are Ardelyx's analysts' financial forecasts?

Ardelyx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $389.04M (high $517.87M, low $324.18M), average EBITDA is $-346M (high $-288M, low $-460M), average net income is $-26.661M (high $-13.055M, low $-37.571M), average SG&A $1.45B (high $1.94B, low $1.21B), and average EPS is $-0.113 (high $-0.0553, low $-0.159). ARDX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $675M (high $869.74M, low $571.13M), average EBITDA is $-600M (high $-508M, low $-773M), average net income is $162.78M (high $223.83M, low $130.21M), average SG&A $2.52B (high $3.25B, low $2.13B), and average EPS is $0.69 (high $0.949, low $0.552).

Did the ARDX's actual financial results beat the analysts' financial forecasts?

Based on Ardelyx's last annual report (Dec 2022), the company's revenue was $52.16M, beating the average analysts forecast of $30.19M by 72.75%. Apple's EBITDA was $-62.126M, missing the average prediction of $-71.059M by -12.57%. The company's net income was $-67.207M, missing the average estimation of $-153M by -55.95%. Apple's SG&A was $76.6M, beating the average forecast of $42.53M by 80.11%. Lastly, the company's EPS was $-0.42, missing the average prediction of $-0.58 by -27.57%. In terms of the last quarterly report (Sep 2023), Ardelyx's revenue was $56.39M, beating the average analysts' forecast of $22.57M by 149.86%. The company's EBITDA was $7.4M, missing the average prediction of $-20.063M by -136.87%. Ardelyx's net income was $6.63M, missing the average estimation of $-25.379M by -126.12%. The company's SG&A was $32.66M, missing the average forecast of $84.33M by -61.27%. Lastly, the company's EPS was $0.03, missing the average prediction of $-0.108 by -127.89%